Match Document Document Title
7618802 Compositions of coronaviruses with a recombination-resistant genome  
The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are...
7601356 Methods and compositions for increasing replication capacity of an influenza virus  
In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza...
7588769 Viruses encoding mutant membrane protein  
A method to prepare viruses with a mutant membrane protein gene, and viruses obtained by the method, are provided.
7579007 Production of “biological carriers” for induction of immune responses and inhibition of viral replication  
This application provides a method to form non-infectious Biological Carrier that may be used to deliver signals to cells either in vitro or in vivo. The Biological Carriers are inactivated virus...
7572455 Vaccine comprising an attenuated pestivirus  
Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein E rns and at least another mutation in the coding sequence for N...
7563449 Methods for reducing cattle reproductive diseases  
The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV)...
7560118 Attenuated dengue virus comprising mutations in the NS3 gene  
A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
7556957 Coronavirus-like particles comprising functionally deleted genomes  
The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs)...
7556940 Assembly of wild-type and chimeric influenza virus-like particles (VLPs)  
Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA,...
7556814 Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane  
An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the...
7544362 N protein mutants of porcine reproductive and respiratory syndrome virus  
The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified...
7517531 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4  
The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4,...
7510863 Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making  
The present invention is directed to novel avian pneumovirus strain Colorado (APV/CO) genes and intergenic sequences. Also disclosed are methods of making recombinant avian pneumovirus and...
7510862 Polynucleotide fragments of an infectious human endogenous retrovirus  
Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from...
7507415 West nile virus vaccine  
The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.
7494799 Paramunity inducers based on attenuated rabbit myxoma virus  
The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease....
7491400 Pharmaceutical compositions comprising attenuated HIV-1 nef-deficient viral particles  
A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion...
7491399 In Ovo vaccine against infectious bursal disease  
The present invention relates to a non pathogenic vaccine comprising a recombinant Infectious Bursal Disease virus that includes a recombinant Segment A, designated as rD78GLSNSΔ, that includes...
7476389 Papillomavirus vaccines  
A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in related to infections caused by papilloma virus. The...
7465574 Recombinant RSV virus expression systems and vaccines  
The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present...
7452542 Live attenuated coronavirus vaccines  
The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may...
7439058 HBV/HCV virus-like particle  
Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface...
7419816 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS  
A mutant virus contains a mutation at a phosphorylation site in one or more viral proteins, which attenuates the virus, and an improved vaccine composition. The invention also relates to methods of...
7413889 Production of a parvovirus vaccine in plants as viral coat protein fusions  
The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in...
7393527 Method for limiting the growth of cancer cells using an attenuated measles virus  
A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the...
7384643 Recombinant poxvirus  
Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the...
7374768 Viral vaccines  
A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the...
7364729 Method of inducing a CTL response  
Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system....
7351527 Immunizing fish against viral infection  
The present invention provides the isolated causative agent of the disease affecting Cyprinus carpino and a method for its isolation. The invention further provides avirulent forms, e.g.,...
7344723 Self-replicating RNA molecule from hepatitis C virus  
A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that...
7335364 Modified Vaccinia Ankara virus variant  
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell...
7332322 Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof  
The present invention provides a Venezuelan equine encephalitis virus replicon RNA useful in the development of stable lines of mammalian, avian and insect cells in which these replicons will...
7309493 Inactivated bovine scours vaccines, process and method of preventing bovine scours  
Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of...
7285381 Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same  
The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also...
7276333 Viral infection inhibitor targeting integrase N-terminal domain  
The object of the present invention is to provide a screening method of a new integrase inhibitor being able to inhibit an HIV infection before the reverse transcription step and having a...
7252984 Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use  
The present invention relates to new attenuated mutant New Castle's disease La SotaNewcastle disease virus strains suitable for in ovo vaccination of avian species comprising a mutation in the gene...
7244558 Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines  
The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the...
7244434 Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines  
The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing...
7238672 Chimeric lyssavirus nucleic acids and polypeptides  
The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a ...
7235235 Alphavirus RNA replicon systems  
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper...
7229625 Retrovirus-like particles made non-infectious by a plurality of mutations  
Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product,...
7223584 Recombinant rabies vaccine and methods of preparation and use  
Live rabies virus vaccines comprising a recombinant rabies virus genome which overexpresses the rabies virus G protein increase apoptotic activity in infected cells, and enhance the generation of...
7211378 Filovirus vectors and noninfectious filovirus-based particles  
Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.
7211260 Infectious bursitis vaccine  
The present invention is concerned with isolated infectious bursitis (or bursal) disease virus(es) and a vaccine containing said virus(es) which is capable of protecting poultry against disease...
7189401 Live attenuated viruses for use as vectors or vaccines  
The present invention provides modified viral genomes for use as vaccines or vectors, which are improved in their ability to retain attenuating mutations. The genomes are from viruses that...
7186543 Preparation of vaccines using a photosensitizer and light  
Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective,...
RE39494 Inactivated mycoplasma hyopneumoniae and uses therefor  
The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of...
7157266 Structure of adenovirus bound to cellular receptor car  
Disclosed is a mutant CAR-DI-binding adenovirus which has a genome comprising one or more mutations in sequences which encode the fiber protein knob domain wherein the mutation causes the encoded...
7153510 Recombinant vesiculoviruses and their uses  
The invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable...
7150984 Attenuated human rotavirus vaccine  
The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating...